18 results about "Pterin" patented technology

The present invention pertains to novel modified terpene synthases and their use for a preparation method for pseudopterosin intermediates and / or pseudopterosins. The method is based on the use of a modified terpene synthase comprising at least one modified amino acid residue, which enables a terpene synthase-catalyzed increased production of pseudopterosin intermediates and / or pseudopterosins from Geranylgeranyl pyrophosphate as starting material. The new modified terpene synthases of this invention allow the production of pseudopterosin intermediates, such as Isoelisabethatriene A, Isoelisabethatriene B, Erogorgiaene, or Seco-Pseudopterosin and / or the production of pseudopterosins, such as Pseudopterosin A, in a cost-efficient, economical, and sustainable manner. Also provided are nucleic acids, encoding for the modified terpene synthases of this invention, as well as expression vectors capable of expressing such nucleic acids and host cells comprising the same.

The present invention features compositions including sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for the treatment of BH4-related disorders. In some embodiments, these compositions and methods result in an increase in plasma. CSF, and / or brain exposure of sepiapterin.

The present invention relates to use of biopterin compounds such as 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin or 4-Amino-(6R,S)-7,8-dihydro-L-biopterin for treating a human patient suffering from a disease condition or disorder that is associated with an increased glutamate level. The invention also relates to the use of such biopterin compounds in a method of treating or preventing glutamate excitotoxicity (glutamate storm) in a patient suffering from a condition that has the potential to result in a pathologically high glutamate level in the brain.

The present invention relates to new pharmaceutical salts and / or co-crystals of sepiapterin which exhibit improved properties. In particular, the invention relates to salts of sepiapterin with improved stability. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts and / or co-crystals of sepiapterin, as well as methods of treating tetrahydrobiopterin-related disorders including administration of a sepiapterin salt and / or co-crystal of the invention to a subject in need thereof.

Disclosed is a method of method of treating a disease in a subject, comprising the step of administering to a subject in need thereof a solution of a solid pharmaceutical composition containing a compound of formula (I) and / or formula (II), wherein the disease is selected from the group consisting of traumatic brain injury, non-traumatic brain injury, elevated cranial pressure, witha compound having formula (I) being:and a compound having the formula (II) being:

The invention discloses a tranexamic acid-tyrosinase inhibitor hybrid conjugate as well as a preparation method and application thereof, belongs to the technical field of cosmetics and biological medicines, and particularly relates to a tranexamic acid-tyrosinase inhibitor hybrid conjugate shown in a formula (I) and a skin composition taking the compound as an active component. According to the hybrid conjugate, tranexamic acid and a tyrosinase inhibitor are integrated into a single-structure molecule through an ester bond, so that the transdermal efficiency can be improved and the transdermal dynamic difference limitation of a traditional compound preparation can be broken through by adjusting the hydrophilic-hydrophobic balance of the compound; and plasmin activity can be inhibited through cooperation of tranexamic acid, so that melanin generation signal transmission capability and tyrosinase inhibition capability of tyrosinase inhibitor specificity are reduced, and efficient and mild multi-channel whitening and spot fading are realized. As a whitening active matter, the tranexamic acid-tyrosinase inhibitor hybrid conjugate disclosed by the invention has a great application prospect in the aspects of whitening and freckle removing effects.

To provide methods of treating BH4-related disorders such as CNS disorder.SOLUTION: A method comprises a step for administering to a subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof, without food. Preferably, the effective method should be an amount sufficient to produce a concentration of at least 0.5 ng / mL in a plasma of the subject within one hour of administration.SELECTED DRAWING: None

The invention belongs to the technical field of food processing and quality safety control, and particularly relates to a specific metabolic marker combination for identifying a drying mode of high-calcium vegetable ox ear powder and application of the specific metabolic marker combination. The metabolic marker composition is prepared from 12 kinds of metabolites, namely, larch sibirica flavone, 9-Methyl-arylchromenone, larch resinol, docosapentaenoic acid, gibberellin A7, methyl-arylpyranone, docosapentaenoyl glycerophosphorylcholine, Cratoxyborenone E, heptanol, prenylflavonoids, pteridin-6-carboxylic acid and Garcimangosone B. The invention further discloses a preparation method of the metabolic marker composition. The metabolic marker combination provided by the invention can be used for carrying out production process traceability and authenticity identification on the high-calcium vegetable ox ear powder, and can be used as a basis for evaluating a product drying process quality standard and monitoring the consistency of a drying process.

The present invention relates to new pharmaceutical salts and / or co-crystals of sepiapterin which exhibit improved properties. In particular, the invention relates to salts of sepiapterin with improved stability. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts and / or co-crystals of sepiapterin, as well as methods of treating tetrahydrobiopterin-related disorders including administration of a sepiapterin salt and / or co-crystal of the invention to a subject in need thereof.

The present invention presents pharmaceutical compositions comprising sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for treating BH4-related disorders. In some embodiments, these compositions and methods result in increased plasma exposure to BH4.

The invention provides methods for treating radiation exposure in a subject by administering sepiapterin, tetrahydrobiopterin, or dihydrobiopterin.

The application discloses a preparation and application method of a selective magnetic solid-phase extraction material for a pterin compound, the nano-composite material is composed of a ferroferric oxide nano-particle core layer, a modification layer I and a modification layer II; the application also discloses a preparation method of the nano-composite material, and discloses a method for magnetically extracting the pterin compound in a complex sample by using the nano-composite material. The functionalized nano-composite material modified by the modification liquid I and the modification liquid II in sequence has a selective magnetic solid-phase extraction effect on the pterin compound in a complex sample, and can be applied to the extraction and detection of the pterin compound.

The application discloses a detection method of B vitamins, wherein the detection method comprises the following steps: preparation of a control sample solution: B vitamin control samples are respectively dissolved to obtain the control sample solution; preparation of a sample solution: a sample solution containing B vitamins is diluted to obtain the sample solution; determination: high performance liquid chromatography is used to determine the content of B vitamins in the sample solution containing B vitamins. The method has good repeatability, high accuracy, high stability, good separation effect and high separation degree for detecting VB1, riboflavin, nicotinamide, pantothenic acid, vitamin B6, biotin, folic acid, vitamin B12, nicotinic acid and pterin, and can be simultaneously used for common detection of multiple B vitamins in a hyaluronic acid complex solution, thereby providing a good means for research and development and quality evaluation of the hyaluronic acid complex solution.

[Problem] To provide a production method for obtaining a pteroic acid amide at a high yield without using a protecting group. [Solution] A method for producing a pteroic acid amid compound, the production method including using an amino compound and a condensing agent together with pteroic acid as a starting material in the presence of a basic compound in a solvent containing an organic solvent so as to thereby obtain a pteroic acid amide compound.